Xin Lang Cai Jing·2026-01-09 02:26Core Viewpoint - The stock price of CanSino Biologics has shown a mixed performance, with a year-to-date increase of 7.96% and a significant rise of 7.96% over the last five trading days, while experiencing a decline of 9.23% over the past 60 days [2]. Group 1: Stock Performance - As of January 9, CanSino's stock price increased by 2.01%, reaching 67.85 CNY per share, with a total market capitalization of 16.762 billion CNY [1]. - The stock has seen a trading volume of 26.03 million CNY, with a turnover rate of 0.34% [1]. - The company has experienced a net outflow of 2.5963 million CNY from main funds, with large orders showing a buy of 3.3886 million CNY and a sell of 4.9386 million CNY [1]. Group 2: Company Overview - CanSino Biologics, established on January 13, 2009, and listed on August 13, 2020, is based in Tianjin and focuses on the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [2]. - The company's main revenue source is vaccine and related product sales, accounting for 97.84% of total revenue, while other income contributes 2.16% [2]. - As of September 30, the number of shareholders increased to 17,700, with an average of 0 circulating shares per person [2]. Group 3: Financial Performance - For the period from January to September 2025, CanSino reported a revenue of 693 million CNY, reflecting a year-on-year growth of 22.13% [2]. - The net profit attributable to the parent company reached 14.4401 million CNY, marking a significant increase of 106.49% year-on-year [2]. - The company has distributed a total of 198 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 4: Shareholding Structure - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 1.3566 million shares as a new shareholder [3].